Kaplan Andre
Division of Nephrology, University of Connecticut Health Center, Farmington, Connecticut 06030, USA.
Semin Dial. 2012 Mar-Apr;25(2):152-8. doi: 10.1111/j.1525-139X.2011.01026.x. Epub 2012 Feb 9.
In general, therapeutic apheresis is a relatively safe procedure with the most commonly seen complications caused by citrate-induced hypocalcemia and urticarial reactions to the protein-containing replacement fluid. Depletion coagulopathy and immunoglobulin depletion must be anticipated when albumin is used as the replacement fluid and becomes more profound as the number of treatment increases. The most serious complications are seen when there is an anaphylactoid reaction to the multiple units of fresh frozen plasma required when used as the replacement fluid. The overall incidence of death is 0.05%, but many of these deaths were in patients with severe preexisting conditions in which the apheresis procedure, itself, may not have been the precipitating cause. As with all extracorporeal treatments requiring large bore vascular access, catheter-related trauma, clotting, infection, and bleeding may also occur.
一般来说,治疗性血液成分单采是一种相对安全的操作,最常见的并发症是枸橼酸盐诱导的低钙血症以及对含蛋白质置换液的荨麻疹反应。当使用白蛋白作为置换液时,必须预见到消耗性凝血病和免疫球蛋白消耗,且随着治疗次数的增加会变得更加严重。当对用作置换液的多个单位新鲜冰冻血浆发生类过敏反应时,会出现最严重的并发症。总体死亡率为0.05%,但这些死亡中的许多发生在已有严重基础疾病的患者中,在这些患者中,血液成分单采操作本身可能并非诱发原因。与所有需要大口径血管通路的体外治疗一样,也可能发生与导管相关的创伤、凝血、感染和出血。